You are hereDecember 10, 2018
Researchers Evaluate pMSCs Sheets for Engineered Repair and Regeneration of Heart Tissue
BOSTON, MA (US), December 2018 — The placenta offers an abundant source of placenta-derived mesenchymal stem cells (pMSCs), which a new study has shown can readily form cell sheets that could be implanted in children with congenital heart defects and offer benefits for heart repair and regeneration compared to commonly used synthetic material-based scaffolds.
Congenital heart disease is the leading cause of birth-defect-related illness and death. The placenta can be readily collected at birth and the cells harvested for pediatric reparative procedures, as described in the study published recently in Tissue Engineering, Part A.
Sitaram Emani, M.D., Breanna Piekarski, R.N., and Sirisha Emani, Children's Hospital, Boston, and Erin Roberts, Kevin Huang and Joyce Wong, Ph.D., Boston University, participated in the study. They evaluated MSCs independent of their source, demonstrated their ability to form cell sheets and described other beneficial effects related to paracrine section and cell-cell interactions at the site of MSC implantation.
The ability of MSCs to secrete factors to induce cardioprotection, stimulate angiogenesis and promote migration, proliferation and differentiation of local cardiac stem cells can all affect tissue repair.
"Excitingly, the study demonstrates that undifferentiated placental MSCs support the migration and proliferation of cardiac cells, ultimately establishing a pathway toward cardiac tissue regeneration," said Tissue Engineering co-editor-in-chief John P. Fisher, Ph.D., director of the NIH Center for Engineering Complex Tissues at the University of Maryland.